Schizophrenia is a severe psychiatric disease with a strong genetic component. Brain-derived neurotrophic factor (BDNF) has been implicated in the pathogenesis of schizophrenia and bipolar (BP) disorders. The present study has examined two polymorphisms in linkage disequilibrium in the BDNF gene, which have been variously reported as associated with schizophrenia and BP. In our study, 321 probands with a primary diagnosis of schizophrenia or schizoaffective disorder, and 263 with a diagnosis of bipolar affective disorder, were examined together with 350 controls drawn from the same geographical region of Scotland. The val66met single-nucleotide polymorphism (SNP) showed significant (P ¼ 0.005) association for valine (allele G) with schizophrenia but not bipolar disorder. Haplotype analysis of val/ met SNP and a dinucleotide repeat polymorphism in the putative promoter region revealed highly significant (Po1 Â 10 À8 ) under-representation of the methionine or met-1 haplotype in the schizophrenic but not the BP population. We conclude that, although the val66met polymorphism has been reported to alter gene function, the risk may depend upon the haplotypic background on which the val/met variant is carried.
Schizophrenia is a major mental illness with a complex multifactorial aetiology involving environmental and genetic contributions. 1 Twin family and adoption studies have demonstrated that the genetic component may account for around half the overall risk. The mode of inheritance is non-Mendelian and recent meta-analyses of genome-wide scans suggest that multiple loci of moderate effect may be involved. 2 Unfortunately, although nearly 3000 meioses were examined in schizophrenia, only one region on chromosome 2p met the criterion for genome-wide significance. 3 All other regions only achieved nominal significance. These studies highlight the limitations of recombination studies in families to detect loci of modest effect and suggest that the use of linkage disequilibrium (LD) analysis of candidate genes may be the method of choice. 4 Brain-derived neurotrophic factor (BDNF) has been implicated in schizophrenia and mood disorders. It influences dopamine receptor expression 5 and elicits rapid postsynaptic effects on ion channels and NMDA receptors in hippocampus. 6 Animal models of schizophrenia and mood disorders show developmental, stress related, and changes of BDNF factor expression following administration of antipsychotic drugs. [7] [8] [9] [10] Abnormal expression of BDNF and its receptor have been reported in the corticolimbic system of schizophrenic patients.
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The BDNF gene is localized to the boundary of chromosome 11p13 and 14. 12 The region does not feature as a significant linkage region in the recent genome-wide meta-analyses, but has generated an LOD score of 1.89 in nonparametric analyses of bipolar families, 13 and an LOD of 1.95 in Costa Rican families.
14 Most family-based and case-control association studies of BDNF1 gene and functional psychoses have examined a polymorphic dinucleotide repeat 15 sequence located 1040 base pairs upstream from the transcription start site of the 1.6 kilobase BDNF mRNA transcript. At least five studies have shown no association of this dinucleotide polymorphism with schizophrenia. [16] [17] [18] [19] [20] An exception is a positive association found in a family study in Italian subjects. 21 More recent studies have examined an SNP that determines a valine-to-methionine variation at codon 66 of the BDNF coding sequence. 22 This functional polymorphism may affect human memory and hippocampal function. 23 The author recently reported a positive association between the Valine or G allele at codon 66 and bipolar disorder in Canadians of European descent. 22 A similar excess of the Valine (G allele) in Caucasian but not Japanese bipolars is reported in other studies. 24, 25 There have been fewer reports of the val66met polymorphism and schizophrenia. Sample sizes have been small and results mostly negative. 23, 26, 27 In view of the potential importance of BDNF gene in major mental illness, we have tried to resole these conflicting findings by examining schizophrenia and bipolar disorder in a large homogeneous out-bred Scottish population using a combination of these two polymorphisms of the BDNF gene in a case-control study.
Materials and Methods
In our study, 321 probands with a primary diagnosis of schizophrenia or schizoaffective disorder and 263 with a diagnosis of bipolar affective disorder were examined together with 350 controls drawn from the same geographical region of Scotland. All were of Caucasian origin. The schizophrenic and control groups have been described previously. 28, 29 All bipolar disorders diagnosed by case note examination, clinical interview, and OPCRIT met the DSM 1 V criteria for primary diagnosis. The mean age of the sample is 34710 years, and the mean age of onset is 1977.3 years. All patients were recruited through psychiatric hospitals in Scotland with the permission of consulting psychiatrists. The study was approved by the Multiregional Research Ethics Committee (MREC) and written informed consent to participate in the study was obtained.
Subjects were typed for the G/A (valine-methionine) variation at position 758 of the BDNF gene (BDNF (MIM 113505)) coding sequence using data from the National Center for Biotechnology Information SNP database (reference number rs6265).
A 53-bp fragment was amplified by PCR, hybridized to probes complementary to the sequence containing the SNP, and subsequently visualized using the standard Dynamic Allele Specific Hybridization (DASH) assay protocol and software. 30 Primer sequences were as follows: 5 0 -ACA TCA TTG GCT GAC ACT TTC G-3 0 for the forward primer and 5 0 -GGT CCT CAT CCA ACA GCT CTT C-3 0 for the reverse primer. The reverse primer is biotinylated at the 5 0 end, allowing the reverse strand to be bound to a streptavidin-coated microtitre plate. An oligonucleotide probe complementary to the bound singlestranded DNA is hybridized to the target at low temperature, forming a duplex DNA region that interacts with a double strand-specific intercalating dye. Probe sequences complementary to the primer sequences were: 5 0 -TGC AAC ACG TGA TAG AA-3 0 for the G probe and 5 0 -TCG AAC ACA TGA TAG AA-3 0 for the A probe. Probe-target denaturation is measured over a wide temperature range by monitoring fluorescence while heating. All tested sequences yield a melting temperature indicative of either perfect match or single-base mismatch to the assay probe. DASH genotypes were double validated using both of the allele-specific probes. Since this was a novel assay design, we also confirmed the accuracy of our DASH genotypes using the RFLP method, 22 where 12 individuals were randomly selected for regenotyping from every panel of 48 DASH genotypes. There were no ambiguities in our genotyping results. The BDNF dinucleotide-repeat polymorphism located 1040 base pairs upstream from the transcription start site of the 1.6-kb BDNF mRNA in the putative promoter region was examined as reported previously by another author. 15 The microsatellite and val66met polymorphisms are separated by approximately 1280 basepairs and have been previously reported to be in strong LD. 22 PCR was performed on 25 ng of template DNA to amplify a fragment containing the dinucleotide-repeat polymorphism, and PCR products were sized by capillary electrophoresis on MegaBACE (Pharmacia) 31 Genotype frequencies were obtained by using the program Phase 32 and for the haplotype results we used the Monte Carlo method. 33 The degree of LD between the two markers, as determined by the two-locus LD program, 32 produced a D 0 value of 0.569 with a global disequilibrium w 2 ¼ 477.72 (5 df; Po0.00001). Our current sample sizes are large enough to ensure reasonable power for the LD performed. 34 The accession number for BDNF is MIM 113505 and the G/A (valine-methionine) variation at position 758 of the BDNF coding sequence is rs6265.
Results
In our combined sample of schizophrenia, bipolar and controls, frequencies for the alleles of the val66met polymorphism were met (A) ¼ 19.4% and val (G) ¼ 80.6%. We found four common alleles of the dinucleotide-repeat polymorphism of the BDNF gene (allele 1 ¼ 18.5%, allele 2 ¼ 3%, allele 3 ¼ 70.0%, and allele 4 ¼ 6%), with a heterozygosity of 47%. The total sample was in Hardy-Weinberg equilibrium when the rare genotypes were removed. Table 1 shows the genotype frequencies of the val66met polymorphism across the three groups of subjects. There is a significant excess of val (G) allele (Table 1 ) present in the schizophrenic compared to the control group (w 2 ¼ 7.89, P ¼ 0.0049, OR ¼ 1.48, upper 95% CI ¼ 1.95; lower CI ¼ 1.13). There was no difference between the bipolar group and controls (w 2 ¼ 0.377, P ¼ 0.54). There were no significant differences in dinucleotide allele frequencies or genotype distributions among the three study groups (data not shown). Table 2 shows the distributions and frequencies of the haploypes when the two polymorphisms are combined, in schizophrenia, bipolar and control subjects. The most striking observation is a highly significant decrease (Po1 Â 10
À8
, OR ¼ 0.30, upper 95% CI ¼ 0.47, lower CI ¼ À0.77) in frequency of the met-1 haplotype in the schizophrenic group compared to controls (6.2 vs 17.8%, respectively). Multiple tests were carried out and the corrected level of significance when the Bonferroni 35 correction is applied still remains significant. The corrected P-values were as follows: val-1 haplotype P-value ¼ 0.04; met-1 haplotype Po4.65 Â 10
À7
.
Discussion
Our study is the first to date to have examined a large schizophrenia sample, comparing haplotype frequencies for the combined val66met and the BDNF dinucleotide-repeat polymorphism. It shows a highly significant under-representation of the met-1 haplotype among schizophrenics. The met-1 deficit is paralleled by a significant excess of the val-1 haplotype. Positive findings in case-control studies can occur as a result of population stratification. However, to date, we have found no evidence of stratification. We have compared pooled allele frequencies between cases and controls on over 30 markers (unpublished data). Schizophrenia cases were also compared to controls on 20 microsatellite markers spanning chromosome 8p outside the NRGI region by deCODE genetics. 29 This study also showed no evidence of stratification.
Our results suggest that the met-1 haplotype is protective against schizophrenia. A previous study has reported met-1 to have a significant decreased transmission to probands with bipolar in a familybased association study. 22 Our study shows a trend in this direction in our bipolar sample, but is nonsignificant. We find a significant excess of the valine allele in the val66met polymorphism. This on its own is insufficient to account for the increased risk of schizophrenia, since the frequencies of the most common haplotype val-3 are almost identical in the three groups: schizophrenia 65%, bipolar 66%, and controls 64.2%, respectively. Differences in risk are principally due to the decreased frequency of the met-1 haplotype and due to the increased frequency of the val-1 haplotype in the schizophrenic group. Indeed when the dinucleotide repeat alone is examined, no significant differences are detected, which may account for the largely negative findings in schizophrenia when this repeat on its own has been examined. Similarily, we only find a modest significant association between the common valine allele of val66met in schizophrenia. Previous reports on smaller sample sets have failed to find significant differences.
It is interesting to consider how possessing the met-1 or val-1 haplotype alters the risk of schizophrenia. Substantial circumstantial evidence has shown that the valine-to-methonine substitution at codon 66 produces functional differences. 23 In humans, the met allele is associated with poorer episodic memory and on neuro-imaging, abnormal hippocampal activity. Neurons transfected with met BDNF GFP showed lower depolarization-induced secretion, and met BDNF with green fluorescence protein (GFP) failed to localize to secretory granules or synapses. It was suggested that the val/met change exerts these effects by impacting intracellular trafficking and activitydependent secretion of BDNF. 36 We suggest that the haplotype background on which the val/met substitution operates influences the overall risk. It is possible that the dinucleotide repeat itself directly affects BDNF expression. More likely, the 1 allele is in LD with a regulatory element upstream of the transcription start site that influences gene expression. The area contains several CpG islands and a series of VNTRs, variants in several of which might alter transcription binding and/or regulatory activity. We are currently investigating this hypothesis. BDNF elicits rapid postsynaptic effects on NMDA receptors. 37 It is noteworthy that in the last year promising positive association studies have been reported between schizophrenia and NRG1,
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DTNBP1,
39
G72,
40 DAAO, 41 PRODH 42 and PPP3CC genes. 43 All relate among other things to glutaminergic transmission and indeed Neuregulin 1 expression is controlled by BDNF. Our results are preliminary, but if confirmed in an independent series, raise exciting possibilities for exploring novel pharmacological targets for schizophrenia, as well as examining for possible gene/gene interactions involving the NMDA complex.
